AR053889A1 - Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) [4-(4-piridilmetil) ftalazin-1-llo] no micronizado y sus sales - Google Patents
Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) [4-(4-piridilmetil) ftalazin-1-llo] no micronizado y sus salesInfo
- Publication number
- AR053889A1 AR053889A1 ARP060102363A ARP060102363A AR053889A1 AR 053889 A1 AR053889 A1 AR 053889A1 AR P060102363 A ARP060102363 A AR P060102363A AR P060102363 A ARP060102363 A AR P060102363A AR 053889 A1 AR053889 A1 AR 053889A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- immediate release
- drug load
- high drug
- pharmaceutical formulations
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 title abstract 2
- 229960002944 cyclofenil Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 2
- -1 (4-chlorophenyl) [4- (4-pyridylmethyl) -phthalazin-1-yl] Chemical class 0.000 abstract 1
- 239000007836 KH2PO4 Substances 0.000 abstract 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 abstract 1
- 239000012738 dissolution medium Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 abstract 1
- 235000019796 monopotassium phosphate Nutrition 0.000 abstract 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formulaciones farmacéuticas solidas de liberacion inmediata y con una carga elevada de droga que comprenden (4-clorofenil)[4-(4-piridilmetil)-ftalazin-.1-ilo] no micronizado, y sales del mismo aceptables para uso farmacéutico. Reivindicacion 1: Una formulacion farmacéutica solida caracterizada porque comprende al menos 50% en peso, respecto de la formulacion total, de (4-clorofenil)[4-(4-piridilmetil)-ftalazin-1-ilo] no micronizado, o una sal de éste aceptable para el uso farmacéutico, donde al menos 70% de dicho (4-clorofenil)[4-(4-piridilmetil)-ftalazain-1-ilo], o una sal de éste aceptable para el uso farmacéutico, se disuelve a partir de dicha formulacion farmacéutica solida en 30 minutos, lo que se determina con el método con paletas USP 28, usando amortiguador de KH2PO4/HCl 0,05 M ajustado a pH, 3,0 a 36sC como medio de disolucion, y 50 rpm como velocidad de agitacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05090166A EP1731153A1 (en) | 2005-06-07 | 2005-06-07 | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| and salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053889A1 true AR053889A1 (es) | 2007-05-23 |
Family
ID=34938467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102363A AR053889A1 (es) | 2005-06-07 | 2006-06-07 | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) [4-(4-piridilmetil) ftalazin-1-llo] no micronizado y sus sales |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP1731153A1 (es) |
| JP (1) | JP2008542420A (es) |
| KR (1) | KR20080031005A (es) |
| CN (1) | CN101242840A (es) |
| AR (1) | AR053889A1 (es) |
| AU (1) | AU2006256852A1 (es) |
| BR (1) | BRPI0613393A2 (es) |
| CA (1) | CA2610975A1 (es) |
| CR (1) | CR9563A (es) |
| DO (1) | DOP2006000127A (es) |
| EC (1) | ECSP078038A (es) |
| GT (1) | GT200600242A (es) |
| IL (1) | IL187905A0 (es) |
| MX (1) | MX2007015494A (es) |
| NO (1) | NO20080065L (es) |
| PE (1) | PE20070319A1 (es) |
| RU (1) | RU2007147951A (es) |
| TW (1) | TW200716115A (es) |
| UY (1) | UY29582A1 (es) |
| WO (1) | WO2006131393A1 (es) |
| ZA (1) | ZA200800112B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1958616A1 (en) * | 2007-02-13 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
-
2005
- 2005-06-07 EP EP05090166A patent/EP1731153A1/en not_active Withdrawn
-
2006
- 2006-06-06 KR KR1020087000236A patent/KR20080031005A/ko not_active Withdrawn
- 2006-06-06 GT GT200600242A patent/GT200600242A/es unknown
- 2006-06-06 MX MX2007015494A patent/MX2007015494A/es not_active Application Discontinuation
- 2006-06-06 JP JP2008515151A patent/JP2008542420A/ja active Pending
- 2006-06-06 EP EP06762010A patent/EP1888072A1/en not_active Withdrawn
- 2006-06-06 CN CNA2006800294742A patent/CN101242840A/zh active Pending
- 2006-06-06 WO PCT/EP2006/005600 patent/WO2006131393A1/en not_active Ceased
- 2006-06-06 PE PE2006000619A patent/PE20070319A1/es not_active Application Discontinuation
- 2006-06-06 CA CA002610975A patent/CA2610975A1/en not_active Abandoned
- 2006-06-06 BR BRPI0613393-2A patent/BRPI0613393A2/pt not_active IP Right Cessation
- 2006-06-06 RU RU2007147951/15A patent/RU2007147951A/ru not_active Application Discontinuation
- 2006-06-06 AU AU2006256852A patent/AU2006256852A1/en not_active Abandoned
- 2006-06-06 TW TW095120062A patent/TW200716115A/zh unknown
- 2006-06-07 UY UY29582A patent/UY29582A1/es not_active Application Discontinuation
- 2006-06-07 DO DO2006000127A patent/DOP2006000127A/es unknown
- 2006-06-07 AR ARP060102363A patent/AR053889A1/es unknown
-
2007
- 2007-12-05 IL IL187905A patent/IL187905A0/en unknown
- 2007-12-06 CR CR9563A patent/CR9563A/es not_active Application Discontinuation
- 2007-12-19 EC EC2007008038A patent/ECSP078038A/es unknown
-
2008
- 2008-01-04 ZA ZA200800112A patent/ZA200800112B/xx unknown
- 2008-01-04 NO NO20080065A patent/NO20080065L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1888072A1 (en) | 2008-02-20 |
| ECSP078038A (es) | 2008-01-23 |
| CN101242840A (zh) | 2008-08-13 |
| IL187905A0 (en) | 2008-03-20 |
| WO2006131393A1 (en) | 2006-12-14 |
| MX2007015494A (es) | 2008-02-22 |
| PE20070319A1 (es) | 2007-04-12 |
| KR20080031005A (ko) | 2008-04-07 |
| EP1731153A1 (en) | 2006-12-13 |
| CA2610975A1 (en) | 2006-12-14 |
| DOP2006000127A (es) | 2006-12-15 |
| AU2006256852A8 (en) | 2006-12-14 |
| JP2008542420A (ja) | 2008-11-27 |
| RU2007147951A (ru) | 2009-07-20 |
| CR9563A (es) | 2008-02-20 |
| TW200716115A (en) | 2007-05-01 |
| ZA200800112B (en) | 2010-06-30 |
| BRPI0613393A2 (pt) | 2011-01-11 |
| UY29582A1 (es) | 2007-01-31 |
| GT200600242A (es) | 2007-02-09 |
| NO20080065L (no) | 2008-03-06 |
| AU2006256852A1 (en) | 2006-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
| CY1121782T1 (el) | Διαδικασια για ξηρανση της bibw2992, tων αλατων αυτης και στερεων φαρμακευτικων σκευασματων που περιλαμβανουν αυτο το δραστικο συστατικο | |
| AR078846A1 (es) | Composicion para el tratamiento de la enfermedad de alzheimer | |
| NO20083027L (no) | Kontrollert frigivelses-fastformpreparat | |
| HRP20090340T1 (hr) | Derivati 5-fenil-4-metil-tiazol-2-il-amina kao inhibitori enzima fosfatidilinozitol 3-kinaza (pi3) za liječenje upalnih bolesti dišnih puteva | |
| ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
| TR200801336T1 (tr) | Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler. | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| ECSP088587A (es) | Compuestos de piperidina 3,5-sustituida como inhibidores de renina | |
| CO6612204A2 (es) | Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina | |
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| CL2011000625A1 (es) | Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida. | |
| EA201070806A1 (ru) | Состав медленного высвобождения на основе ассоциации гликогена и альгината | |
| AR053889A1 (es) | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) [4-(4-piridilmetil) ftalazin-1-llo] no micronizado y sus sales | |
| AR054377A1 (es) | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) (4-piridilmetil) ftalazin -1-il0) micronizado y sus sales | |
| EA201000701A1 (ru) | 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465 | |
| JP2014534215A5 (es) | ||
| DK1653923T3 (da) | Oral afleveringssystem omfattende en bivæsket skum | |
| MX2007013327A (es) | Formulaciones de liberacion prolongada. | |
| ATE417619T1 (de) | Sporopollenin enthaltende lösliche zusammensetzung und verwendung | |
| WO2008016165A3 (en) | Liquid preparation | |
| CA2553231A1 (en) | Amine salt of carbostyril derivative | |
| AR062674A1 (es) | Formulacion acuosa que comprende un agente antitumoral | |
| WO2012039768A3 (en) | Itraconazole formulations | |
| PE20090425A1 (es) | Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinadicarboxamida como inhibidores de renina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |